I

    Intellia Therapeutics Inc (NTLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.73
    -0.14 (-1.09%)

    Market Cap: $1.80B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -4.88%
    Streak
    8 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.79
    Range$-0.89 - $-0.71
    15 analysts
    EPS Revisions
    4
    0
    7d
    4
    5
    30d
    EPS Estimate Drift
    90d ago$-0.79-0.4%
    60d ago$-0.79+0.0%
    30d ago$-0.78+1.2%
    7d ago$-0.79-0.4%
    Current$-0.79
    Revenue Consensus
    $10M
    Range$0 - $15M
    15 analysts
    Dec 31, 2026
    EPS Consensus$-0.68
    Range$-0.94 - $-0.24
    16 analysts
    Revenue Consensus
    $15M
    Range$-13846640 - $63M
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.68---
    Sep 26EST
    		-$-0.79---
    Jun 26
    		$-0.80$-0.80+0.00%Beat+19.2%
    Mar 26
    		$-0.81$-0.90+10.00%Beat+26.4%
    Dec 25
    		$-0.83$-0.99+16.16%Beat+34.6%
    Sep 25
    		$-0.92$-0.98+6.12%Beat+31.3%
    Jun 25
    		$-0.99$-1.03+3.88%Beat+34.9%
    Mar 25
    		$-1.10$-1.27+13.39%Beat+1.8%
    Dec 24
    		$-1.27$-1.32+3.52%Beat+13.0%
    Sep 24
    		$-1.34$-1.37+2.19%Beat+2.9%
    Jun 24
    		$-1.52$-1.20-26.67%Miss-8.6%
    Mar 24
    		$-1.12$-1.36+17.65%Beat+4.3%
    Dec 23
    		$-1.46$-1.44-1.39%Miss-4.3%
    Sep 23
    		$-1.38$-1.50+8.00%Beat+7.4%
    Jun 23
    		$-1.40$-1.33-5.26%Miss-5.3%
    Mar 23
    		$-1.17$-1.38+15.22%Beat+40.3%
    Dec 22
    		$-1.40$-1.39-0.72%Miss-28.4%
    Sep 22
    		$-1.49$-1.25-19.20%Miss-53.6%
    Jun 22
    		$-1.33$-1.30-2.31%Miss-31.7%
    Mar 22
    		$-1.96$-1.11-76.58%Miss-184.1%
    Dec 21
    		$-1.09$-0.94-15.96%Miss-58.0%
    Sep 21
    		$-0.97$-0.85-14.12%Miss-106.4%
    Jun 21
    		$-1.01$-0.61-65.57%Miss-65.6%
    Mar 21
    		$-0.69$-0.66-4.55%Miss-9.5%
    Dec 20
    		$-0.69$-0.61-13.11%Miss-21.1%
    Sep 20
    		$-0.47$-0.57+17.54%Beat+4.1%
    Jun 20
    		$-0.61$-0.67+8.96%Beat-8.9%
    Mar 20
    		$-0.63$-0.42-50.00%Miss-28.6%
    Dec 19
    		$-0.57$-0.56-1.79%Miss-32.6%
    Sep 19
    		$-0.49$-0.61+19.67%Beat+7.5%
    Jun 19
    		$-0.56$-0.59+5.08%Beat-7.7%
    Mar 19
    		$-0.49$-0.57+14.04%Beat+3.9%
    Dec 18
    		$-0.43$-0.56+23.21%Beat+29.5%
    Sep 18
    		$-0.53$-0.49-8.16%Miss-20.5%
    Jun 18
    		$-0.52$-0.56+7.14%Beat-15.6%
    Mar 18
    		$-0.51$-0.56+8.93%Beat-41.7%
    Dec 17
    		$-0.61$-0.42-45.24%Miss-96.8%
    Sep 17
    		$-0.44$-0.49+10.20%Beat-100.0%
    Jun 17
    		$-0.45$-0.42-7.14%Miss-
    Mar 17
    		$-0.36$-0.35-2.86%Miss-
    Dec 16
    		$-0.31$-0.22-40.91%Miss-
    Sep 16
    		$-0.22$-0.21-4.76%Miss-

    Key Metrics

    Valuation
    P/E Ratio-3.79EV/EBITDA-5.51x
    Price/FCF-4.87xFCF Yield-20.52%
    Profitability
    Profit Margin0.00%Operating Margin-1472.00%
    ROE-55.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio6.65xQuick Ratio6.65x
    Trading Statistics
    Beta1.79Avg Volume3.45M
    52-Week High$28.2552-Week Low$7.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.81
    SMA 20$12.28
    SMA 50$13.15
    SMA 200$12.47
    EMA 10$12.75
    EMA 20$12.52
    EMA 50$12.74
    EMA 200$12.92

    MACD

    Line: 0.17Signal: 0.02Hist: 0.15

    ADX

    ADX: 18.8+DI: 23.2-DI: 20.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down4.0
    PSAR$13.71

    Bollinger Bands

    Upper Band$13.72
    Lower Band$10.84
    %B Position2345%(Upper)
    Band Width0.66

    RSI (14-Day)

    Neutral
    52.1

    Momentum Oscillators

    Stoch %K64.4
    Stoch %D72.1
    Williams %R-43.1
    ROC (10d)5.3%
    Momentum0.64
    CCI (20d)46.8
    MFI (14d)39.0

    Volatility Measures

    ATR (14d)$0.72(5.7%)
    StdDev (20d)0.72
    Hist Vol74.6%(High)

    Volume Flow

    VWAP$12.67
    OBV10.7M
    AD Line-75.8M
    CMF (20d)0.131

    Volume Metrics

    Avg Vol (20d)3.5M
    Vol Ratio0.8x
    VWMA (20d)$12.27

    Pivot Points

    R3$14.16
    R2$13.82
    R1$13.35
    Pivot Point$13.01
    S1$12.54
    S2$12.20
    S3$11.73

    Advanced Oscillators

    TSI5.69
    Ultimate Osc54.0
    KST38.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.66M$15.05M$23.02M$13.78M$14.24M$16.63M$12.87M$9.11M$6.96M$28.93M$-1,917,000$11.99M
    Cost of Revenue$0$0$6.01M$0$0$0$116.88M$0$0$0$2.47M$0
    Gross Profit$7.66M$15.05M$23.02M$13.78M$14.24M$16.63M$12.87M$9.11M$6.96M$28.93M$-1,917,000$11.99M
    Operating Expenses$120.42M$115.58M$121.73M$125.26M$124.24M$137.43M$149.32M$153.88M$146.00M$142.94M$138.07M$143.10M
    R&D$82.59M$80.74M$88.65M$94.75M$97.03M$108.43M$116.88M$123.38M$114.21M$111.85M$108.98M$113.70M
    SG&A$37.82M$34.84M$33.08M$30.51M$27.21M$29.01M$32.44M$30.50M$31.79M$31.09M$28.99M$29.40M
    Operating Income$-112,760,000$-100,532,000$-98,710,000$-111,477,000$-109,996,000$-120,807,000$-136,447,000$-144,770,000$-139,043,000$-114,003,000$-139,892,000$-131,107,000
    Interest Income$6.13M$4.30M$2.92M$10.15M$8.74M$6.48M$7.55M$9.06M$-7,932,000$6.57M$7.73M$8.88M
    Interest Expense$0$0$0$0$0$0$0$0$8.14M$0$0$0
    Income Before Tax$-107,424,000$-96,231,000$-95,744,000$-100,987,000$-101,659,000$-113,877,000$-127,138,000$-135,712,000$-147,183,000$-108,257,000$-127,532,000$-121,928,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-106,634,000$-96,231,000$-95,786,000$-101,324,000$-101,255,000$-114,329,000$-128,898,000$-135,712,000$-146,975,000$-107,436,000$-132,161,000$-122,224,000
    EBITDA$-112,082,000$-98,865,000$-93,479,000$-107,289,000$-109,593,000$-120,137,000$-137,483,000$-146,443,000$-141,301,000$-117,597,000$-139,104,000$-136,444,000
    EBIT$-113,550,000$-100,532,000$-98,668,000$-111,140,000$-110,400,000$-120,355,000$-136,447,000$-144,770,000$-139,251,000$-114,824,000$-135,263,000$-130,811,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NTLA

    News

    Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer LEONARD JOHN M

    This document is a statement of changes in beneficial ownership of securities for Officer Leonard John M at Intellia Therapeutics. It reports alterations in his holdings of the company's securities, as required by regulatory guidelines.

    Moomoo•8/25/26•
    Neutral

    Cathie Wood’s ARK buys Intellia stock, sells Roblox

    Cathie Wood's ARK ETFs made significant portfolio adjustments on August 24, 2026. The firm invested heavily in Intellia Therapeutics (NTLA), purchasing 169,357 shares across its ARKK and ARKG ETFs. Concurrently, ARK continued to reduce its stake in Roblox Corp (RBLX), selling 26,199 shares, reflecting a strategic shift towards promising biotech stocks and away from gaming and entertainment.

    Investing.com•8/25/26•
    Bullish

    Intellia Therapeutics (NTLA) CEO sells shares around $13

    Intellia Therapeutics (NTLA) CEO John M. Leonard sold a total of 22,675 shares of common stock in August 2026 under a pre-arranged Rule 10b5-1 trading plan. The sales occurred on August 20, 2026, and August 21, 2026, at weighted average prices around $12.60 to $13.00 per share, totaling approximately $287,000. Additionally, 58,415 shares are held indirectly by the John M. Leonard 2015 Irrevocable Trust.

    Stock Titan•8/24/26•
    Somewhat-Bearish

    4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

    This article highlights four gene-editing biotech stocks—CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Beam Therapeutics (BEAM), and Editas Medicine (EDIT)—as promising long-term investments. It details their differentiated technologies, clinical pipelines, and market positions, emphasizing gene editing's potential to revolutionize medicine by addressing diseases at their genetic source. While acknowledging the technology's transformative potential, the article also points out ongoing challenges related to delivery, safety, manufacturing, and regulatory approval.

    TradingView•8/24/26•
    Bullish

    Intellia Therapeutics Inc Stock Historical Valuations | XTER:38I

    This page provides a stock summary for Intellia Therapeutics Inc (XTER:38I), including its current stock price (€11.1), market capitalization (€1.54B), P/B ratio (2.47), and enterprise value (€1.23B) as of August 21. It also notes that GuruFocus has detected three severe warning signs for the stock and offers a 7-day free trial to access more detailed analysis.

    GuruFocus•8/24/26•
    Bearish

    Frequently Asked Questions About NTLA

    Does NTLA pay dividends?
    Intellia Therapeutics Inc (NTLA) does not currently pay a regular dividend.
    What is NTLA's market cap?
    Intellia Therapeutics Inc (NTLA) has a market capitalization of $1.80B with a current stock price of $12.73.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In